Inter-digestive and post-prandial antro-pyloro-duodenal motor activity in humans: Effect of 5-hydroxytryptamine 1 receptor agonism

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 7, 2004, Pages 805-815

  Calvert, E L ^a   Whorwell, P J ^a   Houghton, L A ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b WITHINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DUODENUM; EVALUATION; FEMALE; GASTROINTESTINAL MOTILITY; HUMAN; MALE; MOTOR ACTIVITY; NORMAL HUMAN; PRIORITY JOURNAL; PYLORUS; STOMACH ANTRUM;

ADOLESCENT; ADULT; DIGESTION; DUODENUM; FASTING; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MANOMETRY; MOTOR NEURONS; POSTPRANDIAL PERIOD; PYLORUS; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 1942438197     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01901.x     Document Type: Article

References (59)

1. Sanger GJ. 5-Hydroxytryptamine and functional bowel disorders. Neurogastroenterol Motil 1996; 8: 319-31.
2. Spiller RC. Effects of serotonin on intestinal secretion and motility. Curr Opin Gastroenterol 2001; 17: 99-103.
3. Tack J, Sarnelli G. Serotonergic modulation of visceral sensation: upper gastrointestinal tract. Gut 2002; 51(Suppl. 1): i77-80.
4. Bearcroft CP, Perrett D, Farthing MJG. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998; 42: 42-6.
5. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52: 663-70.
6. Lea R, Houghton LA, Whorwell PJ, Whitaker RP. Evidence for increased plasma 5-hydroxytryptamine (5-HT) concentration following meal ingestion in patients with functional dyspepsia (FD) and its relationship to gender and symptoms. Gastroenterology 2002; 122(4): 304.
7. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
8. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6.
9. 4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 577-85.
10. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745-51.
11. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
12. Tack J, Ligozio DG, Sue S, Lefkowitz M, Vandeplassche L. A phase II placebo controlled randomised trial with tegaserod (T) in functional dyspepsia (FD) patients with normal gastric emptying (NGE). Gastroenterology 2002; 122(4): 154.
13. 3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149-59.
14. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-55.
15. 3 antagonist in subjects with diarrhoea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2671-6.
16. 3 receptor antagonist, delays colonic transit in both patients with irritable bowel syndrome, and healthy volunteers. Aliment Pharmacol Ther 2000; 14: 869-78.
17. Talley NJ, Van Zanten SV, Saez LR, et al. A dose-ranging, placebo-controlled, randomised trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 525-37.
18. 3 antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther 2002; 16: 225-33.
19. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 1346-52.
20. 1-like agonist, on liquid emptying in man. Aliment Pharmacol Ther 1992; 6: 685-91.
21. 1-receptor agonist, induces a lag phase for the emptying of liquids in humans. Am J Physiol 1997; 272: G902-8.
22. 1 receptor-mediated relaxation of gastric fundus. Am J Physiol 1999; 276: G373-7.
23. Read NW, Houghton LA. Physiology of gastric emptying and pathophysiology of gastroparesis. In: Ouyang A, ed. Gastroenterology Clinics of North America, 18(No. 2). Philadelphia: W.B. Saunders, 1989: 359-74.
24. Boeckxstaens GE, Hirsch DP, Kuiken SD, Heisterkamp SH, Tytgat GNJ. The proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol 2002; 97: 40-8.
25. Tack J, Coulie B, Wilmer A, Peeters T, Janssens J. Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive gastrointestinal motility in man. Gut 1998; 42: 36-41.
26. Houghton LA, Read NW, Heddle R, et al. Motor activity of the gastric antrum, pylorus and duodenum under fasted conditions and after a liquid meal. Gastroenterology 1988; 94: 1276-84.
27. Houghton LA, Read NW, Heddle R, et al. Relationship of the motor activity of the antrum, pylorus and duodenum to gastric emptying of a solid-liquid mixed meal. Gastroenterology 1988; 94: 1285-91.
28. Kwong NK, Brown BH, Whittaker G, Duthie HL. Electrical activity, motility and acid secretion of the human stomach. Br J Surg 1970; 57: 384.
29. Duthie HJ, Brown BH, Robertson-Dunn B, Kwong NK, Whittaker GE, Waterfall W. Electrical activity in the gastroduodenal area - slow waves in the proximal duodenum: a comparison of man and dog. Am J Dig Dis 1972; 17: 344-51.
30. Heddle R, Fone D, Dent J, Horowitz M. Stimulation of pyloric motility by intraduodenal dextrose in normal subjects. Gut 1988; 29: 1349-57.
31. Houghton LA, Kerrigan DD, Read NW. Effect of intragastric infusion of acid on the antropyloroduodenal motor unit in human volunteers. J Gastrointest Motil 1990; 2(3): 202-8.
32. Heddle R, Dent J, Read NW, et al. Antropyloroduodenal motor responses to intraduodenal lipid infusion in healthy volunteers. Am J Physiol 1988; 254: G671-9.
33. Fone DR, Horowitz M, Maddox A, Akkermans LM, Read NW, Dent J. Gastroduodenal motility during the delayed gastric emptying induced by cold stress. Gastroenterology 1990; 98: 1155-61.
34. Peeters TL, Janssens J, Vantrappen G. Somatostatin and the interdigestive migrating motor complex in man. Regul Pept 1983; 5: 209-17.
35. Tack J, Janssens J, Vantrappen G, et al. Dose-related effect of erythromycin on gastroduodenal motility and plasma motilin levels. Studies in healthy volunteers and in patients with diabetic gastroparesis. Gastroenterology 1991; 103: 72-9.
36. Stanghellini V, Malagelada J-R, Zinsmeister AR, Go VLW, Kao PC. Stress-induced gastrointestinal motor disturbances in humans: possible humoral mechanisms. Gastroenterology 1983; 85: 83-91.
37. Jones K, Edelbroek M, Horowitz M, et al. Evaluation of antral motility in humans using manometry and scintigraphy. Gut 1995; 37: 643-8.
38. Camilleri M, Malagelada J-R, Brown ML, Becker G, Zinsmeister AR. Relation between antral motility and gastric emptying of solids and liquids in humans. Am J Physiol 1985; 249: G580-5.
39. Jacobs F, Akkermanns LMA, Oei HY, Hoekstra A, Wittebol P. A radioisotope method to quantify the function of fundus, antrum, and their contractile activity in gastric emptying of a semi-solid and solid meal. In: Weinbeck M, ed. Motility of the Digestive Tract. New York: Raven Press, 1982: 233-40.
40. Tougas G, Anvari M, Dent J, Somers S, Richards D, Stevenson GW. Relationship of pyloric motility to pyloric opening and closure in healthy subjects. Gut 1992; 33: 466-71.
41. Heddle R, Collins P, Dent J, et al. Motor mechanisms associated with slowing of the gastric emptying of a solid meal by an intraduodenal lipid infusion. J Gastroenterol Hepatol 1989; 4: 437-44.
42. Anvari M, Malbert C-H, Dent J, Jamieson GG. Mechanics of pulsatile transpyloric flow in the pig. J Physiol (Lond) 1995; 488: 193-202.
43. Horowitz M, Dent J, Fraser R, Sun WM, Hebbard G. Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 1994; 39(Suppl. 12): 7S-13S.
44. Malbert C-H, Mathis C. Antropyloric modulation of transpyloric flow of liquids in pigs. Gastroenterology 1994; 107: 37-46.
45. Sun WM, Doran S, Jones KL, et al. Effects of nitroglycerin on liquid gastric emptying and antropyloroduodenal motility. Am J Physiol 1998; 275: G1173-8.
46. Beattie DT, Connor HE, Feniuk W, et al. The pharmacology of sumatriptan. Rev Contemp Pharmacother 1994; 5: 285-94.
47. Tack J. Receptors of the enteric nervous system: potential targets for drug therapy. Gut 2000; 47(Suppl. IV:): iv20.
48. Sleight AJ, Cervenka A, Peroutka SJ. In vivo effects of sumatriptan (GR43175) on extracellular levels of 5-HT in the guinea-pig. Neuropharmacology 1990; 29: 511-3.
49. Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992; 43: 776-98.
50. Russo A, Fraser R, Adachi K, Horowitz M, Boeckxstaens G. Evidence that nitric oxide mechanisms regulate small intestinal motility in humans. Gut 1999; 44: 72-6.
51. Sun WM, Doran S, Lingerfelser TH, et al. Effects of glyceryl trinitrate on the pyloric motor response to intraduodenal triglyceride infusions in humans. Eur J Clin Invest 1996; 26: 657-64.
52. 1B/D receptor antagonists. Am J Physiol 2003; 285: G96-104.
53. Kaumann AJ, Parsons AA, Brown AM. Human arterial constrictor serotonin receptors. Cardiovasc Res 1993; 27: 2094-103.
54. Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994; 344: 985-6.
55. 1 agonist, sumatriptan. Aliment Pharmacol Ther 1999; 13: 927-36.
56. 1 agonist, on the frequency of transient lower esophageal sphincter relaxations and gastroesophageal reflux in healthy subjects. Am J Gastroenterol 1999; 94: 3158-64.
57. 1 agonist, increases gastroesophageal reflux. Gut 1998; 42: A64(Abstract).
58. Foster JM, Houghton LA, Whorwell PJ. Further evidence that sumatriptan induced chest pain is oesophageal in origin: effect of oesophageal visceral sensation. Gastroenterology 1997; 112: A733(Abstract).
59. Chester AH, O'Neil GS, Yaccoub MH. Sumatriptan and ischaemic heart disease. Lancet 1993; 341: 1419-20.